Lupin shares fall 6% after CLSA cuts target price, US FDA issues observations
Updated : May 16, 2019 10:47 AM IST
Shares of Lupin fell 4 percent intra-day after brokerages remain bearish on the stock, and the US FDA (United Stated Food and Drug Administration) gives out three observations for its Aurangabad-based manufacturing facility.
Meanwhile, Lupin also clarified on the issue of US filing lawsuit against generic drug companies.
Most brokerages are bearish on the stock. CLSA and Credit Suisse maintained 'sell' rating.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more